NCT05738616View on ClinicalTrials.gov

Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)

PHASE3RecruitingINTERVENTIONAL

Enrollment

196

Participants

Timeline

Start Date

May 10, 2024

Primary Completion Date

May 1, 2027

Study Completion Date

December 1, 2027

Conditions

Advanced Hepatocellular Carcinoma

Interventions

COMBINATION_PRODUCT

Lenvatinib combined with TACE and Camrelizumab

Once subjects have signed the informed consent and passed screening, they will be randomized in a 1:1 ratio to either the experimental arm (lenvatinib combined with TACE and camrelizumab) or the control arm (lenvatinib combined with TACE).

Trial Locations (1)

610000

RECRUITING

HuaXi hospital, Chengdu

All Listed Sponsors

lead

Wen Tianfu

OTHER